Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NanoGut

Financiado

Cerrado

Exploiting the pathophysiology of the gut towards innovative oral peptide delive...

Exploiting the pathophysiology of the gut towards innovative oral peptide delivery strategies The development of new oral drug delivery systems that will enable the absorption of therapeutic peptides to the systemic circulation is one of the greatest current challenges for the pharmaceutical industry and is the ‘holy grail... ver más

30/06/2025

UCLouvain

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

UNIVERSITE CATHOLIQUE DE LOUVAIN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-10-25

ERC-2019-STG: ERC Starting Grant

I+D

Cerrada hace 6 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UCLouvain

1.49M€ | Lider

SOLER AND PALAU RESEARCH

356.75K€ | Participante

Proyectos interesantes

MOCHA

Medical Technol...

Nanotechnology

157K€ Cerrado

SAF2016-79230-R

Medical Technol...

Nanotechnology

97K€ Cerrado

NANOLEM

Nanotechnology

Medical Technol...

231K€ Cerrado

INTESTINANOS

Nanotechnology

Medical Technol...

2M€ Cerrado

PTQ-13-06076

Medical Technol...

Nanotechnology

71K€ Cerrado

MAT2010-20370

Medical Technol...

Nanotechnology

133K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 68 meses Fecha Inicio: 2019-10-25
Fecha Fin: 2025-06-30

Líder del proyecto

UNIVERSITE CATHOLIQUE DE LOUVAIN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The development of new oral drug delivery systems that will enable the absorption of therapeutic peptides to the systemic circulation is one of the greatest current challenges for the pharmaceutical industry and is the ‘holy grail’ of peptide delivery. Improved novel drug delivery systems are of utmost importance in order to fulfill the potential of this route of administration in the treatment of chronic diseases (e.g. type 2 diabetes mellitus), where daily injections are often required. There are various advantages of using nanocarriers for this purpose: they offer protection against chemical and enzymatic degradation, controlled release, targeting, tolerability and/or improved uptake and translocation resulting in enhanced bioavailability and greater therapeutic efficacy. I was the first to demonstrate that lipid-based nanocarriers trigger endogenous glucagon-like peptide (GLP)-1 and GLP-2 secretion in vivo after orally administered to mice. This effect can be exploited to develop a novel and unconventional drug delivery nanosystem as a promising strategy for the treatment of gastrointestinal disorders (e.g. type 2 diabetes mellitus, Crohn’s disease, ulcerative colitis). There are significant gaps in current knowledge that need to be addressed to make this possible. I propose a series of studies to answer the following key questions: -First, can we develop a dual-action drug delivery nanosystem that synergizes its own biological effect and that of the encapsulated bioactive molecule? -Second, can we ameliorate type 2 diabetes mellitus (T2DM) and inflammatory bowel diseases (IBD) using an oral peptide-loaded dual-action lipid-based nanosystem? –Third, is this innovative strategy a viable alternative to current treatments in T2DM and IBD? By exploiting the gut pathophysiology, I propose an innovative therapeutic approach using cutting-edge advanced technologies to deal with an unmet therapeutical need in the treatment of gastrointestinal disorders.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores